ERBB2 and gastric cancer: In an exploratory cohort in the DESTINY-Gastric01 trial, 44 patients with HER2-low, advanced gastric cancer were treated with T-DXd and achieved an ORR of 17.5% (n = 7 of 40 patients) and median progression-free survival duration of 2.8 to 4.4 months, depending on HER2 expression (patients with an IHC score of 2+ survived longer) [39].